Bose ADDIN EN.CITE Patients with CKD or Placebo/no -0.20 (-0.60, 2014 Allopurinol Proteinuria (g/day) 5 250 NA MD Random decreased kidney treatment 0.10) function Endothelial function Population with Xanthine Placebo/no Flow-mediated Higgins62 2010 5 144 75 MD Random 2.50 (0.15, 4.84) vascular diseases Oxidase treatment dilatation (%) Population with Xanthine Placebo/no 68.80 (18.70, Higgins62 2010 Forearm blood flow 5 148 74 MD Random vascular diseases Oxidase treatment 118.90) Kanbay ADDIN EN.CITE Placebo/no Flow-mediated 2014 General Allopurinol 6 285 142 MD Fixed 2.75 (2.49, 3.01) treatment dilatation (%) Kanbay ADDIN EN.CITE Placebo/no Forearm blood flow 2014 General Allopurinol 5 130 71 MD Fixed 2.62 (2.32, 2.91) treatment (%) Kanbay ADDIN EN.CITE Placebo/no 2014 General Allopurinol dilatation 11 415 213 MD Fixed 2.69 (2.49, 2.89) treatment (%)
Bose ADDIN EN.CITE 2014 Patients with CKD or decreased kidney function Allopurinol Placebo/no treatment Proteinuria (g/day) 5 250 NA MD Random -0.20 (-0.60, 0.10) Endothelial function Higgins62 2010 Population with vascular diseases Xanthine Oxidase Placebo/no treatment Flow-mediated dilatation (%) 5 144 75 MD Random 2.50 (0.15, 4.84) Higgins62 2010 Population with vascular diseases Xanthine Oxidase Placebo/no treatment Forearm blood flow 5 148 74 MD Random 68.80 (18.70, 118.90) Kanbay ADDIN EN.CITE 2014 General Allopurinol Placebo/no treatment Flow-mediated dilatation (%) 6 285 142 MD Fixed 2.75 (2.49, 3.01) Kanbay ADDIN EN.CITE 2014 General Allopurinol Placebo/no treatment Forearm blood flow (%) 5 130 71 MD Fixed 2.62 (2.32, 2.91) Kanbay ADDIN EN.CITE 2014 General Allopurinol Placebo/no treatment dilatation (%) 11 415 213 MD Fixed 2.69 (2.49, 2.89)
Supplementary%20material_v7%20-%20Final-2.docx